ASCO GUIDELINES Bundle

Somatic Genomic Testing for Metastatic or Advanced Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475502

Contents of this Issue

Navigation

Page 3 of 15

4 Key Points Table 1. Select Definitions of Commonly Used Terms in Precision Oncology Term Definition Homologous recombination deficiency (HRD) Cells that cannot efficiently repair damaged DNA via homologous recombination. The companion diagnostic for niraparib defines HRD-positive as detection of deleterious or suspected deleterious mutations within BRCA1 or BRCA2 or a positive GIS. Immunotherapy A type of therapy that activates the body's immune system to target cancer cells. Intertumoral heterogeneity The evolution of tumor cells over time so that the genomic profile differs between the primary and the metastatic sites and/ or amongst multiple metastatic lesions. Intratumoral heterogeneity (ITH) Within the same tumor, different populations of cells within distinct spatial regions have unique genomic alterations. Multigene panel A next-generation sequencing (NGS) test that sequences a defined list of genes with at least 50 genes in total. Mutation A change in the nucleotide sequence encoding for a gene. Mutational signature Combination of mutations that are characteristic of a specific mutagenesis process leading to or contributing to the disease. Minimal residual disease (MRD) e presence of tumor cells that have spread from the primary tumor but are not detectable by imaging. Microsatellite instability (MSI) e presence of nucleotide insertions or deletions at microsatellite loci, which indicates a deficiency in the mismatch repair machinery that normally corrects these errors. • Microsatellites: Highly polymorphic, short, tandem repeats of DNA nucleotides distributed throughout the human genome, prone to replication errors. • Microsatellite instability-high (MSI-H): The presence of a high level of mutations at the sequenced microsatellite loci. Mismatch repair deficiency (dMMR) e loss of function or expression of one or more of the components of the dMMR (typically PMS2, MLH1, MSH2, and MSH6) that recognize mismatches within DNA as a result of injury and initiate the repair process. LOH e loss of the wildtype allele of a gene that was previously in a heterozygous state due to a germline or somatic mutation. LOH can occur at a single gene or as a genome-wide event due to defective DNA repair and be indicative of homologous recombination deficiency. (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Somatic Genomic Testing for Metastatic or Advanced Cancer